1. Home
  2. USIO vs XBIT Comparison

USIO vs XBIT Comparison

Compare USIO & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Usio Inc.

USIO

Usio Inc.

SELL

Current Price

$2.82

Market Cap

83.5M

Sector

Finance

ML Signal

SELL

Logo XBiotech Inc.

XBIT

XBiotech Inc.

SELL

Current Price

$2.12

Market Cap

69.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
USIO
XBIT
Founded
1998
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.5M
69.8M
IPO Year
1999
2015

Fundamental Metrics

Financial Performance
Metric
USIO
XBIT
Price
$2.82
$2.12
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $5.92
N/A
AVG Volume (30 Days)
★ 197.7K
37.4K
Earning Date
11-11-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.01
N/A
Revenue
★ $28,200,535.00
N/A
Revenue This Year
$14.57
N/A
Revenue Next Year
$11.98
$30.47
P/E Ratio
$285.50
★ N/A
Revenue Growth
★ 12.69
N/A
52 Week Low
$1.03
$2.09
52 Week High
$3.06
$3.44

Technical Indicators

Market Signals
Indicator
USIO
XBIT
Relative Strength Index (RSI) 56.50 39.61
Support Level $2.15 N/A
Resistance Level $3.03 $2.46
Average True Range (ATR) 0.17 0.07
MACD 0.01 -0.00
Stochastic Oscillator 67.74 4.55

Price Performance

Historical Comparison
USIO
XBIT

About USIO Usio Inc.

Usio Inc is a cloud-based Fintech payment processor. The company serves multiple industry verticals with technology that facilitates payment acceptance and funds disbursement in a single, full-stack ecosystem. It provides payment acceptance through multiple payment methods, including payment facilitation, prepaid card, and electronic billing products and services to businesses, merchants, and consumers. The company's reportable operating segments are Output Solutions and Merchant Services, and these segments.

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

Share on Social Networks: